Significant Losses Trigger Class Action Possibilities for Capricor Therapeutics Investors

Class Action Alert for Capricor Therapeutics Investors

Introduction

In light of substantial losses suffered by investors in Capricor Therapeutics, Inc. (NASDAQ: CAPR), an opportunity has arisen for claimants to lead a class action lawsuit against the company. Robbins Geller Rudman & Dowd LLP has announced that investors who acquired securities during a specified period from December 17, 2025, to July 26, 2026, can seek appointment as lead plaintiffs by September 28, 2026. This article will delve into the allegations surrounding the company, the nature of the claims involved, and the potential implications for investors.

Background on Capricor Therapeutics

Capricor Therapeutics is a biotechnology firm focused on developing innovative therapies for high-need conditions, specifically Duchenne muscular dystrophy (DMD), a rare genetic disorder marked by progressive muscle deterioration. Their leading therapy candidate, known as Deramiocel, aims to tackle cardiac and skeletal muscle issues that are prominent in patients suffering from DMD. However, recent developments have raised serious legal and ethical questions regarding the company’s practices and communication.

Class Action Allegations

The class action lawsuit against Capricor and its executives alleges multiple discrepancies and misleading representations related to their clinical trials and the submission process for Deramiocel's Biologics License Application (BLA). Specifically, it is claimed that:
1. Alteration of Statistical Analysis Plans: Changes to the pre-specified statistical analysis plan were purportedly made without prior FDA consent. These adjustments could offer a skewed perspective of the clinical data, diminishing the reliability of their findings.
2. Risk of Regulatory Denial: The lawsuit argues that the lack of FDA agreement on the statistical methods raised significant concerns about the likelihood of obtaining regulatory approval for Deramiocel. This jeopardizes not just the product's future but also alters investor projections.
3. Impact of FDA Briefing Documents: Following the FDA's release of briefing documents prior to a July 29, 2026, advisory committee meeting, the stock price plummeted following insights suggesting the BLA failed to provide sufficient evidence for Deramiocel's efficacy. The documents criticized Capricor’s analytical approaches, leading to a 64% drop in share price immediately thereafter.

Current Situation and Next Steps

Investors who have experienced significant losses during the defined class period are encouraged to consider their legal options. Anyone interested in stepping forward as a lead plaintiff should submit their information promptly via Robbins Geller's specified portal. It's essential to understand that serving as a lead plaintiff could provide a stronger platform for influence within the class action suit. The selection of a dedicated law firm for litigation after becoming a lead plaintiff is a critical step toward addressing grievances collectively.

About Robbins Geller Rudman & Dowd LLP

As one of the leading law firms in securities fraud and investor rights litigation, Robbins Geller has gained notable traction in representing investors against corporate malfeasance. With a proven record of over $916 million recovered for investors in 2025 alone, the firm is highly regarded for its strategic legal interventions. Over the past five years, Robbins Geller has amassed a recovery total of approximately $8.4 billion, marking a history of success that emphasizes their capability in navigating complex securities cases.

Conclusion

For investors feeling the impact of Capricor Therapeutics' recent challenges, now is a pivotal moment to consider joining the class action. By participating, concerned stakeholders can stand up for their rights to obtain just remedies for their losses. Interested investors should act swiftly and consult with Robbins Geller to explore their options. The coming weeks will be crucial in determining the direction of this class action and its outcome for all involved investors.